⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921048 | 0.77 | — | — | |
| SCHEMBL1159492 | 0.72 | — | — | |
| SCHEMBL3922472 | 0.72 | — | — | |
| SCHEMBL1664575 | 0.72 | — | — | |
| Formaldehyde SCHEMBL11566715 | 0.72 | — | — | |
| SCHEMBL22105 | 0.71 | — | — | |
| SCHEMBL2428440 | 0.71 | — | — | |
| SCHEMBL18231660 | 0.70 | — | — | |
| Formaldehyde SCHEMBL4378361 | 0.69 | TSHR (0.36) | — | |
| Propene SCHEMBL4935138 | 0.69 | TSHR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451209-A4 | TETRA-,PENTA-,HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2009-06-03 | — | — | EP | claimed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | claimed |
| US-20080071062-A1 | TETRA-, PENTA-, HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | HAVIV FORTUNA | 2008-03-20 | — | — | US | claimed |
| EP-1461356-A4 | HEXA-, HEPTA-, AND OCTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2007-12-12 | — | — | EP | claimed |
| US-20070167376-A1 | Hexa-, Hepta-, and Octapeptides Having Antiangiogenic Activity | HAVIV FORTUNA | 2007-07-19 | — | — | US | claimed |
| EP-1450841-A4 | TRI-, TETRA-, AND PENTA-PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2007-01-24 | — | — | EP | claimed |
| US-7122625-B2 | Hexa-, hepta-, and octapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-10-17 | — | — | US | claimed |
| US-20060194737-A1 | Hepta-, octa-and nonapeptides having antiangiogenic activity | HAVIV FORTUNA | 2006-08-31 | — | — | US | claimed |
| US-7067490-B2 | Hepta-, Octa-and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | claimed |
| US-7037897-B2 | TRI-, TETRA-, and penta-peptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-05-02 | — | — | US | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | claimed |
| EP-1021437-B1 | ARYLSULFONYLIMIDAZOLONE DERIVATIVES AS AN ANTITUMOR AGENT | DONG WHA PHARM IND CO LTD (KR) | 2001-11-14 | — | — | EP | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038347-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | claimed |
| EP-1021437-A1 | ARYLSULFONYLIMIDAZOLONE DERIVATIVES AS AN ANTITUMOR AGENT | DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) | 2000-07-26 | — | — | EP | claimed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | claimed |
| US-5929103-A | ANTICARCINOGENIC AGENTS | DONG WHA PHARM. IND. CO., LTD. (KR) | 1999-07-27 | — | — | US | claimed |
| WO-1998007719-A1 | ARYLSULFONYLIMIDAZOLONE DERIVATIVES AS AN ANTITUMOR AGENT | DONG WHA PHARM. IND. CO., LTD. (KR) | 1998-02-26 | — | — | WO | claimed |